Serotonin Syndrome

Complex MONDO:0018546 Pathograph 26 Show in embeddings browser Poisoning

A drug-induced toxidrome caused by excess serotonergic activity in the central nervous system. It is not a disease of a serotonin defect but of serotonin excess, almost always pharmacological: a serotonergic drug raises synaptic 5-hydroxytryptamine - by increasing synthesis or release, blocking reuptake, blocking metabolism, or directly agonizing receptors - and the resulting over-stimulation of postsynaptic receptors, most notably 5-HT2A and 5-HT1A, produces a clinical triad of altered mental status, neuromuscular hyperexcitability (clonus, hyperreflexia, tremor), and autonomic instability. Most cases follow a combination of two agents acting by different mechanisms, the classic and most dangerous being a monoamine oxidase inhibitor with a serotonin-reuptake inhibitor, but monotherapy and overdose also cause it. Severity is a spectrum: most cases are mild and resolve within about a day of stopping the drug, while the severe end is defined by hyperthermia that is muscular rather than hypothalamic in origin, with rhabdomyolysis, disseminated intravascular coagulation, and death. Diagnosis is clinical, by the Hunter or Sternbach criteria, there being no confirmatory test. Because the hyperthermia is generated by sustained muscle activity rather than a raised set point, antipyretics do not help and the specific antidote is a 5-HT2A antagonist, cyproheptadine.

Ask OpenScientist

Ask a research question about Serotonin Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
15
Phenotypes
1
Gaps
26
Pathograph
3
Medical Actions
4
Differentials
1
Models
1
References
1
Deep Research
?

Discussions and Knowledge Gaps

1
What are the agreed terminology, diagnostic criteria, and boundaries of serotonin syndrome, now that it presents at therapeutic doses and across non-toxicology settings rather than only as overdose in psychiatric patients?
KNOWLEDGE GAP OPEN ss_diagnostic_consensus
Attached to
diagnosis#Hunter Serotonin Toxicity Criteria
The entry already carries the measured disagreement between the Hunter, Sternbach and Radomski criteria (PMID:27406219). The broader problem is that the syndrome's terminology, clinical boundaries, etiology and pathophysiology remain unsettled decades after its description, and the classic toxicology/overdose picture does not match the milder, therapeutic-dose cases now reported from perioperative, neurology, cardiology and pediatric settings. Until a consensus definition exists, prevalence, criterion performance and even which presentations count as serotonin syndrome are all moving targets.
Show evidence (1 reference)
PMID:38855279 SUPPORT REVIEW SYNTHESIS Other
"Since SS is a potentially lethal illness, consensus is required on several concerns related to SS."
A review arguing that terminology, criteria and pathophysiology of serotonin syndrome still lack consensus.
⚙

Pathophysiology

5
Excess Synaptic Serotonin
One or more serotonergic drugs raise the concentration of serotonin at central synapses, by increasing its synthesis or release, blocking its reuptake, inhibiting its monoamine-oxidase metabolism, or directly agonizing receptors. Combinations acting by two different mechanisms - classically a monoamine oxidase inhibitor with a reuptake inhibitor - produce the largest rise.
serotonergic neuron CL:0000850 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves serotonergic neuron (CL:0000850). CL:0000850 is a cell type from the Cell Ontology.
Downstream
Overactivation of Postsynaptic 5-HT Receptors The excess synaptic serotonin over-stimulates postsynaptic serotonin receptors.
Show evidence (5 references)
PMID:2035713 SUPPORT REVIEW SYNTHESIS Human Clinical
"The serotonin syndrome is most commonly the result of the interaction between serotonergic agents and monoamine oxidase inhibitors."
Establishes drug interaction raising serotonergic tone as the proximate cause.
PMID:41194881 SUPPORT PRIMARY RESULT Human Clinical
"Disproportionality analysis identified 68 drugs associated with serotonin syndrome in elderly patients."
A FAERS pharmacovigilance analysis shows how broad the implicated drug set is, across many pharmacologic classes.
PMID:39866251 SUPPORT PRIMARY RESULT Human Clinical
"20 primary care patients with treatment-resistant depression who developed mild serotonin syndrome after starting a second antidepressant"
Adding a second antidepressant to treatment-resistant depression is a common real-world route to (mild) serotonin syndrome.
+ 2 more references
Overactivation of Postsynaptic 5-HT Receptors
Excess serotonin over-activates postsynaptic serotonin receptors, most notably 5-HT2A and also 5-HT1A, driving the downstream neuromuscular, autonomic, and mental-status features of the syndrome.
serotonin receptor signaling pathway GO:0007210 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased serotonin receptor signaling pathway (GO:0007210). GO:0007210 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Neuromuscular Hyperexcitability 5-HT receptor stimulation gives rise to the neuromuscular hyperexcitability that is the main feature of the syndrome.
Central Noradrenergic Hyperactivity In the rat 5-HT syndrome model, inducing the syndrome raises anterior hypothalamic noradrenaline many-fold, and potent 5-HT2A antagonists both block that rise and prevent the hyperthermia and death, placing the noradrenergic surge downstream of 5-HT2A overactivation.
Autonomic Hyperactivity Serotonin receptor overactivation drives autonomic instability, one of the three domains the syndrome consists of.
Agitation Receptor overactivation produces the altered mental status of the syndrome.
Coma At the severe end, the altered mental status deepens from agitation and delirium to coma.
Show evidence (1 reference)
PMID:24358002 SUPPORT REVIEW SYNTHESIS Human Clinical
"overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors"
States the receptor subtypes whose overactivation drives the syndrome.
Neuromuscular Hyperexcitability
Excess serotonergic drive to spinal and brainstem motor pathways produces the neuromuscular hallmark of the syndrome: clonus, hyperreflexia, tremor, and myoclonus, progressing to rigidity in severe cases. Sustained muscle activity generates heat and, when extreme, breaks down muscle.
Downstream
Clonus
Hyperreflexia
Tremor
Myoclonus
Muscle rigidity
Seizure
Hyperthermia Sustained muscle hyperactivity generates heat; the hyperthermia of severe serotonin syndrome is muscular in origin, which is why it is unresponsive to antipyretics.
Rhabdomyolysis Prolonged severe muscle hyperactivity and rigidity cause muscle breakdown.
Show evidence (1 reference)
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"Serotonin syndrome's main feature is neuro-muscular hyperexcitability, which in many cases is mild but in some cases can become life-threatening."
Identifies neuromuscular hyperexcitability as the central feature and its severity spectrum.
Central Noradrenergic Hyperactivity
In animal models of the serotonin syndrome, anterior hypothalamic noradrenaline rises steeply, and the degree of that rise tracks the hyperthermia and lethality. It is a downstream amplifier of the thermoregulatory derangement rather than a primary serotonergic event.
Animal models
Rat clorgyline plus 5-HTP serotonin syndrome model Rat recapitulates Reproduces the hypothalamic noradrenaline surge and shows it is suppressed by 5-HT2A blockade.
Downstream
Hyperthermia The hypothalamic noradrenaline surge contributes to the rise in body temperature; suppressing it with 5-HT2A antagonists prevents the hyperthermia in the rat model.
Show evidence (1 reference)
PMID:11164765 SUPPORT Model Organism
"The noradrenaline (NA) levels in the anterior hypothalamus, measured by microdialysis, increased to 15.9 times the preadministration level."
Documents the hypothalamic noradrenergic surge in the rat 5-HT syndrome model.
Autonomic Hyperactivity
Serotonergic overactivation of autonomic pathways produces the autonomic instability of the syndrome: tachycardia, diaphoresis, mydriasis, and diarrhea, with labile blood pressure in severe cases.
Downstream
Tachycardia
Hyperhidrosis
Mydriasis
Diarrhea
Hypertension
Show evidence (1 reference)
PMID:24358002 SUPPORT REVIEW SYNTHESIS Human Clinical
"a combination of mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity"
Names autonomic hyperactivity as one of the three clinical domains.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Serotonin Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Cardiovascular 2
Hypertension HP:0000822 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertension (HP:0000822). HP:0000822 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"Tachycardia, hypertension and fever were the most common autonomic symptoms."
Hypertension is reported as one of the most common autonomic symptoms.
PMID:41853658 SUPPORT Human Clinical
"Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
A chronic-tramadol case with documented hypertension (140/100 mmHg).
Tachycardia HP:0001649 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tachycardia (HP:0001649). HP:0001649 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"Tachycardia, hypertension and fever were the most common autonomic symptoms."
Tachycardia is reported as one of the most common autonomic symptoms in the case meta-analysis.
Digestive 1
Diarrhea HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"nervousness, insomnia, nausea, diarrhea, tremor, and dilated pupils"
Diarrhea is listed among the features of serotonin toxicity.
Eye 1
Mydriasis HP:0011499 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mydriasis (HP:0011499). HP:0011499 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"nervousness, insomnia, nausea, diarrhea, tremor, and dilated pupils"
Dilated pupils (mydriasis) are listed among the features of serotonin toxicity.
PMID:41853658 SUPPORT Human Clinical
"Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
A chronic-tramadol case documenting mydriasis on examination.
Integument 1
Hyperhidrosis HP:0000975 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diaphoresis, annotated with Hyperhidrosis (HP:0000975). HP:0000975 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2035713 SUPPORT REVIEW SYNTHESIS Human Clinical
"restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor"
Diaphoresis is among the most frequently reported features.
Metabolism 1
Hyperthermia Fever HP:0001945 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperthermia, annotated with Fever (HP:0001945). HP:0001945 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33196298 SUPPORT REVIEW SYNTHESIS Human Clinical
"frequently observed features include hyperthermia, seizures, and high CK activities"
Hyperthermia is a frequently observed feature of fatal serotonin syndrome.
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"only relatively few cases may present with hyperthermia"
Grounds the statement that hyperthermia is present in only a minority of cases.
Musculoskeletal 2
Muscle rigidity Hypertonia HP:0001276 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertonia (HP:0001276). HP:0001276 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"Of neurological symptoms, tremor and hyperreflexia were most frequently reported followed by muscle rigidity/hypertonia"
Muscle rigidity/hypertonia is among the most frequently reported neurological signs.
PMID:41111752 SUPPORT Human Clinical
"muscle rigidity masked the hyperreflexia and myoclonus often used to diagnose serotonin syndrome, making it even more difficult to recognize"
Rigidity can obscure the hyperreflexia and myoclonus the diagnosis relies on.
Rhabdomyolysis HP:0003201 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rhabdomyolysis (HP:0003201). HP:0003201 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33196298 SUPPORT REVIEW SYNTHESIS Human Clinical
"Creatine kinase (CK) activities were elevated (>3 times of the upper limit of normal) in eighteen patients, and it was very high (>25,000 IU/L) in four patients."
Markedly elevated CK documents rhabdomyolysis in severe and fatal cases.
PMID:41652380 SUPPORT Human Clinical
"creatine phosphokinase (CPK) concentration of 20,930 U/L"
A severe overdose case with markedly elevated CPK documenting rhabdomyolysis; this patient met criteria for both serotonin syndrome and neuroleptic malignant syndrome, so it does not isolate serotonin syndrome as the cause.
Nervous System 7
Agitation HP:0000713 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Agitation (HP:0000713). HP:0000713 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12925718 SUPPORT Human Clinical
"clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia"
Agitation is one of the Hunter criteria features, named explicitly.
Clonus HP:0002169 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clonus (HP:0002169). HP:0002169 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:12925718 SUPPORT Human Clinical
"only clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia were needed for accurate prediction of serotonin toxicity"
Clonus is the central discriminating feature of the Hunter decision rules.
PMID:41853658 SUPPORT Human Clinical
"Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
A chronic-tramadol case documenting inducible ankle clonus on examination.
Hyperreflexia HP:0001347 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperreflexia (HP:0001347). HP:0001347 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12925718 SUPPORT Human Clinical
"clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia"
Hyperreflexia is one of the Hunter criteria features.
Tremor HP:0001337 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tremor (HP:0001337). HP:0001337 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2035713 SUPPORT REVIEW SYNTHESIS Human Clinical
"The most frequent clinical features are changes in mental status, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor."
Tremor is among the most frequently reported features.
Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:2035713 SUPPORT REVIEW SYNTHESIS Human Clinical
"changes in mental status, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor"
Myoclonus is among the most frequently reported features.
Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:33196298 SUPPORT REVIEW SYNTHESIS Human Clinical
"frequently observed features include hyperthermia, seizures, and high CK activities"
Seizures are a frequently observed feature of fatal serotonin syndrome.
PMID:41348645 SUPPORT Human Clinical
"He developed serotonin syndrome with spontaneous clonus and seizures, requiring diazepam, sedation, intubation, and ventilation."
A massive-overdose case with spontaneous clonus and seizures at the severe end.
PMID:36297366 REFUTE INDIRECT Model Organism
"Management of tramadol-poisoned patients should take into account that tramadol-induced seizures are mainly related to a GABAergic pathway."
Refutes the serotonergic attribution for tramadol-overdose seizures specifically: the rat data point to a GABAergic mechanism, so not every seizure in a serotonergic-drug patient is a serotonin-syndrome feature.
Coma HP:0001259 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Coma (HP:0001259). HP:0001259 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41084074 SUPPORT BACKGROUND Human Clinical
"more severe symptoms including fever, delirium, and coma"
Coma is named among the severe manifestations of serotonin syndrome.
💊

Medical Actions

3
Discontinuation and supportive care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
The primary treatment is stopping the offending serotonergic agent and providing supportive care - intravenous fluids, sedation, and external cooling. Most cases resolve within about 24 hours of withdrawal.
Show evidence (1 reference)
PMID:2035713 SUPPORT REVIEW SYNTHESIS Human Clinical
"Discontinuation of the suspected serotonergic agent and institution of supportive measures are the primary treatment"
States drug withdrawal plus supportive care as the primary treatment.
Cyproheptadine
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: cyproheptadine CHEBI:4046 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cyproheptadine (CHEBI:4046). CHEBI:4046 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Cyproheptadine, a 5-HT2A receptor antagonist, is the specific antidote for moderate serotonin syndrome. In the rat model the most potent 5-HT2A antagonists tested (ritanserin, pipamperone) completely prevent the hyperthermia and death, which is the mechanistic rationale for antiserotonergic therapy; cyproheptadine itself was protective only at high doses in that model and is used infrequently in fatal human cases.
Mechanism Target:
INHIBITS Overactivation of Postsynaptic 5-HT Receptors — Cyproheptadine blocks 5-HT2A receptors, opposing the receptor overactivation that drives the syndrome.
Show evidence (1 reference)
PMID:11164765 SUPPORT INDIRECT Model Organism
"potent 5-HT(2A) receptor antagonists are the most effective drugs for treatment of the 5-HT syndrome"
5-HT2A antagonism is the mechanistic basis for antidotal therapy; cyproheptadine is the clinical 5-HT2A antagonist, demonstrated in the rat model.
Show evidence (1 reference)
PMID:16227063 SUPPORT REVIEW SYNTHESIS Human Clinical
"administering either a central serotonergic antagonist, such as cyproheptadine or chlorpromazine, a benzodiazepine, or a combination of the two"
Names cyproheptadine as the central serotonergic antagonist used in treatment.
Benzodiazepine sedation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: diazepam CHEBI:49575 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses diazepam (CHEBI:49575). CHEBI:49575 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Benzodiazepines control agitation and the neuromuscular hyperactivity, and in the animal model attenuate the development of hyperthermia.
Mechanism Target:
INHIBITS Neuromuscular Hyperexcitability — GABA-enhancing sedation dampens the neuromuscular hyperactivity and slows the development of hyperthermia.
Show evidence (1 reference)
PMID:12620284 SUPPORT INDIRECT Model Organism
"Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia."
GABA-enhancing drugs attenuate the hyperthermia in the rat model, supporting benzodiazepine use against the neuromuscular state; an animal-model inference.
Show evidence (1 reference)
PMID:16227063 SUPPORT REVIEW SYNTHESIS Human Clinical
"a central serotonergic antagonist, such as cyproheptadine or chlorpromazine, a benzodiazepine, or a combination of the two"
Names benzodiazepines among the standard treatments.
🌍

Environmental Factors

4
Electroconvulsive therapy concurrent with serotonergic agents
No ECTO exposure class exists for electroconvulsive therapy (searched l~electroconvulsive, l~electroshock, l~electric in sqlite:obo:ecto, all empty), so exposure_term is omitted rather than bound to an approximate term.
Electroconvulsive therapy can precipitate serotonin syndrome when given to a patient already taking serotonergic drugs. ECT is thought to enhance central serotonergic neurotransmission, superimposing on the existing drug-raised serotonergic load. In a reported case the syndrome developed after the first ECT session in a patient on bupropion, trazodone, and quetiapine, and did not recur once the concurrent agents were changed.
Show evidence (1 reference)
PMID:25970280 SUPPORT Human Clinical
"Serotonin syndrome developed soon after she received the first session of electroconvulsive therapy (ECT)."
Documents ECT precipitating serotonin syndrome in a patient on serotonergic agents.
Mechanism Target:
TRIGGERS Excess Synaptic Serotonin — ECT superimposed on serotonergic drugs precipitates the syndrome, consistent with ECT adding serotonergic drive on top of the drug-raised synaptic serotonin.
Show evidence (1 reference)
PMID:25970280 SUPPORT Human Clinical
"The superimposing effect of ECT in conjunction with serotonergic agents might contribute to the development of serotonin syndrome."
Attributes the episode to ECT acting on top of the serotonergic drug load.
Cocaine overdose
exposure to cocaine ECTO:9000265 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to cocaine (ECTO:9000265). ECTO:9000265 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Cocaine inhibits presynaptic reuptake of serotonin (along with dopamine and norepinephrine), raising synaptic serotonin, so a massive cocaine overdose can precipitate serotonin syndrome - here as part of a fatal multi-system cocaine toxidrome that also included toxic leukoencephalopathy and central diabetes insipidus, which are separate cocaine effects rather than part of the serotonergic mechanism.
Show evidence (1 reference)
PMID:42764931 SUPPORT Human Clinical
"We report a fatal case of a 44-year-old man presenting with toxic leukoencephalopathy, serotonin syndrome, and central diabetes insipidus following a massive cocaine overdose"
Documents serotonin syndrome following a massive cocaine overdose.
Mechanism Target:
TRIGGERS Excess Synaptic Serotonin — Cocaine's inhibition of presynaptic serotonin reuptake raises synaptic serotonin, the route by which a cocaine overdose drives the syndrome.
Show evidence (1 reference)
PMID:42764931 SUPPORT BACKGROUND Human Clinical
"Its primary pharmacological action involves the inhibition of presynaptic dopamine, norepinephrine, and serotonin reuptake, resulting in an excessive accumulation of synaptic catecholamines and monoamines"
Cocaine blocks serotonin reuptake, the mechanism by which it raises synaptic serotonin and can precipitate the syndrome.
Ayahuasca combined with a serotonergic agent
No ECTO exposure class exists for ayahuasca or its alkaloids (searched l~ayahuasca, l~harmine, l~dimethyltryptamine in sqlite:obo:ecto, all empty), so exposure_term is omitted rather than bound to an approximate term.
Ayahuasca is an Amazonian botanical brew whose beta-carboline alkaloids (harmine, harmaline, tetrahydroharmine) are reversible MAO-A inhibitors. That MAOI activity predisposes users to serotonin syndrome when ayahuasca is combined with another serotonergic agent - here over-the-counter dextromethorphan - the same high-risk MAOI-plus-serotonergic-drug pairing that causes the syndrome with prescription MAOIs.
Show evidence (1 reference)
PMID:42713547 SUPPORT Human Clinical
"We present the case of a 46-year-old man who developed severe serotonin syndrome (SS) complicated by acute respiratory failure after ingesting ayahuasca over three days, followed by over-the-counter dextromethorphan (DXM) and diphenhydramine"
Documents severe serotonin syndrome after ayahuasca combined with dextromethorphan.
Mechanism Target:
TRIGGERS Excess Synaptic Serotonin — Ayahuasca's beta-carboline MAO-A inhibition blocks serotonin breakdown, so combined with another serotonergic agent it raises synaptic serotonin and precipitates the syndrome.
Show evidence (1 reference)
PMID:42713547 SUPPORT BACKGROUND Human Clinical
"the MAOI content of ayahuasca predisposes users to serotonergic toxicity when combined with other serotonergic agents"
The MAO-inhibiting content of ayahuasca is the route by which it raises serotonergic tone and precipitates the syndrome in combination.
Kava supplement use with serotonergic agents
Mechanism proposed but unconfirmed: the authors suggest kavalactone CYP2D6 and MAO inhibition raised the SNRI/metabolite levels ("may have led to"), reported in a single case alongside a concurrent duloxetine-to-venlafaxine transition, so kava's independent role is not established and no influences_mechanisms link is asserted. No ECTO exposure class exists for kava or Piper methysticum (searched l~kava, l~piper methysticum in sqlite:obo:ecto, both empty).
Kava (Piper methysticum) is an over-the-counter botanical supplement. A pediatric case developed prolonged, cyproheptadine-refractory serotonin syndrome during daily kava use while transitioning between two SNRIs (duloxetine to venlafaxine). The authors propose that kavalactone CYP2D6 and monoamine oxidase inhibition raised the SNRI and active-metabolite levels. It is recorded as a reported association rather than a pathograph trigger: the proposed mechanism is offered as a possibility in a single case with a concurrent SNRI overlap, so kava's own role is unconfirmed and no `influences_mechanisms` link is asserted.
Show evidence (2 references)
PMID:40510098 SUPPORT Human Clinical
"We present a pediatric patient who developed prolonged serotonin syndrome after daily use of kava while transitioning from duloxetine to venlafaxine."
Documents serotonin syndrome associated with kava use during an overlapping-SNRI transition.
PMID:40510098 SUPPORT Human Clinical
"Several kavalactones have demonstrated significant CYP2D6 and monoamine oxidase inhibition, which in this case may have led to higher neuronal cleft serotonin-norepinephrine reuptake inhibitor drug and active metabolite concentrations"
The proposed kava mechanism, recorded with its hedge: kavalactone CYP2D6/MAO inhibition may have raised SNRI and metabolite levels, offered as a possibility in this one case.
🔬

Diagnosis

1
Hunter Serotonin Toxicity Criteria
Diagnosis is clinical. The Hunter criteria apply decision rules over clonus, agitation, diaphoresis, tremor, hyperreflexia, hypertonicity, and temperature in a patient on a serotonergic agent. In their derivation study they were reported as more sensitive and specific than the older Sternbach criteria, and are widely treated as the reference standard; a later case meta-analysis (PMID:27406219) found that superiority rests on that one study and that the three criteria systems agree poorly, so the advantage is not independently established.
Show evidence (2 references)
PMID:12925718 SUPPORT Human Clinical
"These new criteria were simpler, more sensitive (84% vs. 75%) and more specific (97% vs. 96%) than Sternbach's criteria."
Reports the diagnostic performance of the Hunter criteria in their derivation study.
PMID:27406219 SUPPORT REVIEW SYNTHESIS Human Clinical
"There is little agreement between current criteria systems for the diagnosis of serotonin syndrome."
The case meta-analysis finds poor agreement between the criteria systems, qualifying the reported Hunter superiority.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Serotonin Syndrome:

Neuroleptic malignant syndrome Not Yet Curated MONDO:0019790
Overlapping Features The principal differential. Both present with hyperthermia, autonomic instability, altered mental status, and increased muscle tone, and the two overlap most in agents with both antidopaminergic and serotonergic activity. They separate on tempo and on the neuromuscular pattern: serotonin syndrome comes on within hours with clonus and hyperreflexia, whereas neuroleptic malignant syndrome evolves over days as an idiosyncratic reaction to neuroleptics with bradykinesia and lead-pipe rigidity.
Distinguishing Features
  • Serotonin syndrome has clonus and hyperreflexia; neuroleptic malignant syndrome has bradykinesia and lead-pipe or cogwheel rigidity.
  • Serotonin syndrome follows a serotonergic agent and onsets within hours; neuroleptic malignant syndrome is an idiosyncratic reaction to neuroleptics evolving over days.
Show evidence (5 references)
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"Unlike serotonin toxicity, neuroleptic malignant syndrome is not dose-related but is an idiosyncratic reaction to neuroleptic drugs. Onset is slower, taking place over days, and it is differentiated from serotonin toxicity by the presence of bradykinesia and lead-pipe or cogwheel rigidity"
States the tempo and neuromuscular features that distinguish the two.
PMID:16227063 SUPPORT REVIEW SYNTHESIS Human Clinical
"NMS typically occurs over hours to days in a patient taking a neuroleptic agent; its recommended treatment is generally the combination of a central dopamine agonist, bromocriptine or L-dopa, and dantrolene"
Contrasts NMS tempo, trigger, and treatment with serotonin syndrome.
PMID:41652380 SUPPORT Human Clinical
"The patient met the diagnostic criteria for both Serotonin Syndrome and Neuroleptic Malignant Syndrome"
The two can overlap: a sertraline-plus-quetiapine case met criteria for both, which is why the distinction can be difficult at the bedside.
+ 2 more references
Malignant hyperthermia of anesthesia MONDO:0018493
Overlapping Features Shares severe hyperthermia and muscle rigidity, but is triggered by volatile anaesthetics during or shortly after surgery rather than by serotonergic drugs, and is treated with dantrolene. It is one of the drug/toxin-induced hyperthermic syndromes whose triggers and treatments differ from serotonin syndrome.
Distinguishing Features
  • Triggered by specific volatile anaesthetics in the surgical/anaesthesia setting, not by serotonergic agents.
  • Treated with dantrolene; serotonin syndrome responds to withdrawal of the serotonergic agent plus supportive care and a 5-HT2A antagonist.
Show evidence (2 references)
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"Malignant hyperthermia is triggered by specific volatile anesthetics during or shortly after surgery"
States the anaesthetic trigger that distinguishes malignant hyperthermia from serotonin syndrome.
PMID:16227063 SUPPORT REVIEW SYNTHESIS Human Clinical
"MH presents rapidly with jaw rigidity, hyperthermia, and hypercarbia. Although it almost always occurs in the setting of surgical anesthesia, cases have occurred in susceptible individuals during exertion. The treatment of MH involves the use of dantrolene"
Gives the surgical-anaesthesia setting and dantrolene treatment that differentiate it from serotonin syndrome.
Anticholinergic toxicity
Overlapping Features Overlaps through hyperthermia, agitation, mydriasis, and tachycardia, but is distinguished at the bedside by normal muscle tone and reflexes and by dry, flushed skin and absent bowel sounds, against the clonus, hyperreflexia, and diaphoresis of serotonin syndrome.
Distinguishing Features
  • Muscle tone and reflexes are normal in anticholinergic toxicity, unlike the hyperreflexia and clonus of serotonin syndrome.
  • Anticholinergic toxicity gives dry, flushed skin and decreased bowel sounds; serotonin syndrome instead gives diaphoresis.
Show evidence (2 references)
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"A distinguishing feature is that muscle tone and reflexes are normal in anticholinergic toxicity"
The normal tone and reflexes of anticholinergic toxicity separate it from serotonin syndrome.
PMID:30315014 SUPPORT REVIEW SYNTHESIS Human Clinical
"Symptoms include dry mouth, dry and flushed skin, urinary retention, decreased bowel sounds, dilated pupils, blurry vision, fever, agitation, delirium, and hallucinations"
Gives the dry, flushed skin and decreased bowel sounds of anticholinergic toxicity, against the diaphoresis of serotonin syndrome.
Alcohol withdrawal syndrome Not Yet Curated MONDO:0005433
Overlapping Features In a patient with alcohol use disorder who is also on serotonergic medication, serotonin syndrome can masquerade as alcohol withdrawal: both give tremor, diaphoresis, autonomic instability, and agitation. What resolves the case is the medication history, a symptom course that runs beyond the expected withdrawal window, and clonus and hyperreflexia that meet the Hunter criteria in a patient on serotonergic agents, pointing to serotonin syndrome.
Distinguishing Features
  • Clonus and hyperreflexia that meet the Hunter criteria in a patient on serotonergic agents point to serotonin syndrome.
  • Serotonin syndrome tracks the serotonergic medication and can continue beyond the typical alcohol-withdrawal timeframe, rather than following the time since the last drink.
Show evidence (3 references)
PMID:40886730 SUPPORT Human Clinical
"Alcohol withdrawal syndrome (AWS) and serotonin syndrome (SS) share several overlapping symptoms, complicating diagnosis in patients with alcohol use disorder (AUD) on serotonergic treatment"
States the overlap that makes alcohol withdrawal a differential for serotonin syndrome.
PMID:40886730 SUPPORT Human Clinical
"Neurological examination revealed hyperreflexia, clonus, and persistent hypertension, fulfilling the Hunter Serotonin Toxicity Criteria for SS"
Clonus and hyperreflexia fulfilling the Hunter criteria resolve the case toward serotonin syndrome.
PMID:40886730 SUPPORT Human Clinical
"he developed worsening tremors, nausea, diarrhea, diaphoresis, muscle twitching, rigidity, and restlessness beyond the typical AWS timeframe"
The symptom course running beyond the expected withdrawal window is what prompted reconsideration toward serotonin syndrome.
🐁

Animal Models

1
Rat clorgyline plus 5-HTP serotonin syndrome model
The standard pharmacological rat model: an MAO-A inhibitor plus a serotonin precursor drives rectal temperature above 40 degrees C with death within 90 minutes, accompanied by a large anterior-hypothalamic noradrenaline surge. Potent 5-HT2A antagonists abolish both.
Species
Rat
Genotype
Wild-type rats dosed with clorgyline (MAO-A inhibitor) and 5-hydroxy-L-tryptophan
Publication
PMID:11164765
Pathograph links
Central Noradrenergic Hyperactivity recapitulates fidelity: moderate observes: organism Reproduces the hypothalamic noradrenaline surge and shows it is suppressed by 5-HT2A blockade.
Limitations: A precursor-plus-MAOI induction in a single species; it omits the human drug-combination context and species differences in 5-HT receptor distribution.
Readouts
Anterior hypothalamic noradrenaline
Direction: INCREASED
Interpretation: Microdialysis measure of the noradrenergic surge in the model.
Show evidence (1 reference)
PMID:11164765 SUPPORT Model Organism
"The noradrenaline (NA) levels in the anterior hypothalamus, measured by microdialysis, increased to 15.9 times the preadministration level."
Quantifies the hypothalamic noradrenaline rise this readout measures.
Show evidence (1 reference)
PMID:11164765 SUPPORT Model Organism
"both potent 5-HT(2A) receptor antagonists, completely prevented the increase in rectal temperature and death of the animals"
5-HT2A antagonists abolish the model's hyperthermia, supporting it as an informative model of the receptor-driven mechanism.
{ }

Source YAML

click to show 
name: Serotonin Syndrome
creation_date: "2026-10-02T02:00:00Z"
description: >-
  A drug-induced toxidrome caused by excess serotonergic activity in the central
  nervous system. It is not a disease of a serotonin defect but of serotonin
  excess, almost always pharmacological: a serotonergic drug raises synaptic
  5-hydroxytryptamine - by increasing synthesis or release, blocking reuptake,
  blocking metabolism, or directly agonizing receptors - and the resulting
  over-stimulation of postsynaptic receptors, most notably 5-HT2A and 5-HT1A,
  produces a clinical triad of altered mental status, neuromuscular
  hyperexcitability (clonus, hyperreflexia, tremor), and autonomic instability.

  Most cases follow a combination of two agents acting by different mechanisms,
  the classic and most dangerous being a monoamine oxidase inhibitor with a
  serotonin-reuptake inhibitor, but monotherapy and overdose also cause it.
  Severity is a spectrum: most cases are mild and resolve within about a day of
  stopping the drug, while the severe end is defined by hyperthermia that is
  muscular rather than hypothalamic in origin, with rhabdomyolysis, disseminated
  intravascular coagulation, and death. Diagnosis is clinical, by the Hunter or
  Sternbach criteria, there being no confirmatory test. Because the hyperthermia
  is generated by sustained muscle activity rather than a raised set point,
  antipyretics do not help and the specific antidote is a 5-HT2A antagonist,
  cyproheptadine.
categories:
- Toxic Exposure Disorder
- Treatment Toxicity
category: Complex
parents:
- Poisoning
synonyms:
- serotonin toxicity
- serotonin toxidrome
disease_term:
  preferred_term: serotonin syndrome
  term:
    id: MONDO:0018546
    label: serotonin syndrome
notes: >-
  Acquired drug-induced toxidrome, not a Mendelian disease: no causal gene, no
  inheritance block, and no OMIM or Orphanet entry. Candidate pharmacogenetic
  modifiers (CYP2D6, CYP2C19, SLC6A4, HTR2A) are hypothesized in the literature
  but no causal or susceptibility variant is established, so none is curated.
  Hyperthermia is bound to HP:0001945 (Fever, "body temperature elevated above
  the normal range") rather than HP:0002047 Malignant hyperthermia, which is the
  distinct RYR1-related anaesthetic entity; the serotonin-syndrome sign is
  elevated body temperature of muscular origin. No GeneReviews chapter exists
  (checked offline; this is not a Mendelian disorder). Severe cases can be
  complicated by acute respiratory distress syndrome requiring mechanical
  ventilation and ECMO (PMID:41084074), and serotonin syndrome can co-occur with
  SIADH-mediated hyponatremia driven by the same serotonergic agents
  (PMID:41732713); the hyponatremia is a parallel adverse reaction rather than a
  step in the serotonergic motor chain, so it is noted here rather than wired
  into the pathograph.
references:
- reference: PMID:12925718
  title: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity."
pathophysiology:
- name: Excess Synaptic Serotonin
  biological_scale: MOLECULAR
  description: >-
    One or more serotonergic drugs raise the concentration of serotonin at
    central synapses, by increasing its synthesis or release, blocking its
    reuptake, inhibiting its monoamine-oxidase metabolism, or directly agonizing
    receptors. Combinations acting by two different mechanisms - classically a
    monoamine oxidase inhibitor with a reuptake inhibitor - produce the largest
    rise.
  chemical_entities:
  - preferred_term: serotonin
    term:
      id: CHEBI:28790
      label: serotonin
    modifier: INCREASED
  cell_types:
  - preferred_term: serotonergic neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  downstream:
  - target: Overactivation of Postsynaptic 5-HT Receptors
    causal_link_type: DIRECT
    description: >-
      The excess synaptic serotonin over-stimulates postsynaptic serotonin
      receptors.
    evidence:
    - reference: PMID:24358002
      reference_title: "Serotonin syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "precipitated by the use of serotonergic drugs and overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors"
      explanation: Links the serotonergic drug exposure to receptor overactivation as the next step.
  evidence:
  - reference: PMID:2035713
    reference_title: "The serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The serotonin syndrome is most commonly the result of the interaction between serotonergic agents and monoamine oxidase inhibitors."
    explanation: Establishes drug interaction raising serotonergic tone as the proximate cause.
  - reference: PMID:41194881
    reference_title: "Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Disproportionality analysis identified 68 drugs associated with serotonin syndrome in elderly patients."
    explanation: >-
      A FAERS pharmacovigilance analysis shows how broad the implicated drug set
      is, across many pharmacologic classes.
  - reference: PMID:39866251
    reference_title: "Evaluating the risk of mild serotonin syndrome in primary care: a retrospective case series of patients with treatment-resistant depression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "20 primary care patients with treatment-resistant depression who developed mild serotonin syndrome after starting a second antidepressant"
    explanation: >-
      Adding a second antidepressant to treatment-resistant depression is a
      common real-world route to (mild) serotonin syndrome.
  - reference: PMID:40704237
    reference_title: "Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "toxicology review concluded that polypharmacy with serotonergic and modulating agents was the likely trigger"
    explanation: >-
      Serotonin syndrome can arise from serotonergic polypharmacy at stable
      therapeutic doses, without any overdose.
  - reference: PMID:41732713
    reference_title: "The interplay between serotonin syndrome and syndrome of inappropriate antidiuresis: a fatal case of acute hyponatremia during treatment with duloxetine, chlorphenamine, amitriptyline, and L-tryptophan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "It is most commonly associated with the combination of two serotonergic agents, but can also occur after the initiation or dose escalation of a single drug in particularly sensitive patients"
    explanation: >-
      A recent fatal case report restating that serotonergic drug combinations,
      or single-agent initiation in sensitive patients, precipitate the syndrome.
- name: Overactivation of Postsynaptic 5-HT Receptors
  biological_scale: MOLECULAR
  description: >-
    Excess serotonin over-activates postsynaptic serotonin receptors, most
    notably 5-HT2A and also 5-HT1A, driving the downstream neuromuscular,
    autonomic, and mental-status features of the syndrome.
  biological_processes:
  - preferred_term: serotonin receptor signaling pathway
    term:
      id: GO:0007210
      label: serotonin receptor signaling pathway
    modifier: INCREASED
  downstream:
  - target: Neuromuscular Hyperexcitability
    causal_link_type: DIRECT
    description: >-
      5-HT receptor stimulation gives rise to the neuromuscular
      hyperexcitability that is the main feature of the syndrome.
    evidence:
    - reference: PMID:27406219
      reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      snippet: "main feature is neuro-muscular hyperexcitability, which, if severe, can become life-threatening. The syndrome is thought to arise from 5HT1A and 5HT2 receptor stimulation"
      explanation: >-
        Ties the neuromuscular hyperexcitability to 5-HT1A/5-HT2 receptor
        stimulation as its origin; a review synthesis, so the causal attribution
        is indirect.
  - target: Central Noradrenergic Hyperactivity
    causal_link_type: DIRECT
    description: >-
      In the rat 5-HT syndrome model, inducing the syndrome raises anterior
      hypothalamic noradrenaline many-fold, and potent 5-HT2A antagonists both
      block that rise and prevent the hyperthermia and death, placing the
      noradrenergic surge downstream of 5-HT2A overactivation.
    evidence:
    - reference: PMID:11164765
      reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: "pretreatment with ritanserin (3 mg/kg) and pipamperone (20 mg/kg), both potent 5-HT(2A) receptor antagonists, completely prevented the increase in rectal temperature and death of the animals, and the hypothalamic NA levels in these two groups increased less than that in the other groups"
      explanation: >-
        5-HT2A blockade suppresses the hypothalamic noradrenaline rise and the
        hyperthermia, so the noradrenergic hyperactivity is downstream of
        receptor overactivation; an animal-model inference.
  - target: Autonomic Hyperactivity
    causal_link_type: DIRECT
    description: >-
      Serotonin receptor overactivation drives autonomic instability, one of the
      three domains the syndrome consists of.
    evidence:
    - reference: PMID:24358002
      reference_title: "Serotonin syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      snippet: "most notably, 5HT-2A receptors. This syndrome consists of a combination of mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity"
      explanation: >-
        Links receptor overactivation to the autonomic-hyperactivity domain the
        syndrome is composed of; a review synthesis, so indirect.
  - target: Agitation
    causal_link_type: DIRECT
    description: Receptor overactivation produces the altered mental status of the syndrome.
    evidence:
    - reference: PMID:24358002
      reference_title: "Serotonin syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
      snippet: "most notably, 5HT-2A receptors. This syndrome consists of a combination of mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity"
      explanation: >-
        Links receptor overactivation to the mental-status domain the syndrome
        is composed of; a review synthesis, so indirect.
  - target: Coma
    causal_link_type: DIRECT
    description: >-
      At the severe end, the altered mental status deepens from agitation and
      delirium to coma.
    evidence:
    - reference: PMID:41084074
      reference_title: "Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "more severe symptoms including fever, delirium, and coma"
      explanation: The severe end of the mental-status spectrum runs through delirium to coma.
  evidence:
  - reference: PMID:24358002
    reference_title: "Serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors"
    explanation: States the receptor subtypes whose overactivation drives the syndrome.
- name: Neuromuscular Hyperexcitability
  biological_scale: ORGANISM
  description: >-
    Excess serotonergic drive to spinal and brainstem motor pathways produces
    the neuromuscular hallmark of the syndrome: clonus, hyperreflexia, tremor,
    and myoclonus, progressing to rigidity in severe cases. Sustained muscle
    activity generates heat and, when extreme, breaks down muscle.
  downstream:
  - target: Clonus
    causal_link_type: DIRECT
  - target: Hyperreflexia
    causal_link_type: DIRECT
  - target: Tremor
    causal_link_type: DIRECT
  - target: Myoclonus
    causal_link_type: DIRECT
  - target: Muscle rigidity
    causal_link_type: DIRECT
  - target: Seizure
    causal_link_type: DIRECT
  - target: Hyperthermia
    causal_link_type: DIRECT
    description: >-
      Sustained muscle hyperactivity generates heat; the hyperthermia of severe
      serotonin syndrome is muscular in origin, which is why it is unresponsive
      to antipyretics.
    evidence:
    - reference: PMID:27406219
      reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "In the context of SS, hyperthermia is linked to increased muscle activity as consequence of hyperexcitability and direct serotonergic effects on the muscle"
      explanation: >-
        Directly attributes the hyperthermia of serotonin syndrome to increased
        muscle activity arising from the neuromuscular hyperexcitability.
    - reference: PMID:33508784
      reference_title: Drug-induced Hyperthermic Syndromes in Psychiatry.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Several psychotropic drug classes and combinations have been associated with a classic clinical syndrome of hyperthermia, skeletal muscle hyper-metabolism, rigidity or rhabdomyolysis, autonomic dysfunction and altered mental status ranging from catatonic stupor to coma."
      explanation: >-
        Places the hyperthermia alongside skeletal-muscle hypermetabolism and
        rigidity as the drug-induced hyperthermic-syndrome picture.
    - reference: PMID:30056864
      reference_title: "Metabolome analysis of the serotonin syndrome rat model: Abnormal muscular contraction is related to metabolic alterations and hyper-thermogenesis."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: "excess expression of UCP-3, which contributes to the hyper-thermogenesis observed in the SS model"
      explanation: >-
        The rat metabolome gives the muscular basis of the heat: anaerobic
        muscle hypermetabolism with UCP-3 upregulation drives the
        hyper-thermogenesis; an animal-model inference.
  - target: Rhabdomyolysis
    causal_link_type: DIRECT
    description: Prolonged severe muscle hyperactivity and rigidity cause muscle breakdown.
    evidence:
    - reference: PMID:27406219
      reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "In cases with rhabdomyolysis, muscle rigidity/hypertonicity, fever and hyperthermia were significantly more frequent"
      explanation: >-
        Rhabdomyolysis co-occurs with the severe neuromuscular state (rigidity
        and hyperthermia), linking it downstream of the muscle hyperactivity.
  evidence:
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Serotonin syndrome's main feature is neuro-muscular hyperexcitability, which in many cases is mild but in some cases can become life-threatening."
    explanation: Identifies neuromuscular hyperexcitability as the central feature and its severity spectrum.
- name: Central Noradrenergic Hyperactivity
  biological_scale: CELLULAR
  description: >-
    In animal models of the serotonin syndrome, anterior hypothalamic
    noradrenaline rises steeply, and the degree of that rise tracks the
    hyperthermia and lethality. It is a downstream amplifier of the
    thermoregulatory derangement rather than a primary serotonergic event.
  downstream:
  - target: Hyperthermia
    causal_link_type: DIRECT
    description: >-
      The hypothalamic noradrenaline surge contributes to the rise in body
      temperature; suppressing it with 5-HT2A antagonists prevents the
      hyperthermia in the rat model.
    evidence:
    - reference: PMID:15048612
      reference_title: "Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: "Pretreatment with risperidone (0.5 mg/kg) and ketanserin (5 mg/kg) prevented the development of hyperthermia and the increase in the NA level."
      explanation: >-
        Blocking the noradrenaline rise prevents hyperthermia in the rat model,
        linking the two; an animal-model inference.
  evidence:
  - reference: PMID:11164765
    reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The noradrenaline (NA) levels in the anterior hypothalamus, measured by microdialysis, increased to 15.9 times the preadministration level."
    explanation: Documents the hypothalamic noradrenergic surge in the rat 5-HT syndrome model.
- name: Autonomic Hyperactivity
  biological_scale: ORGANISM
  description: >-
    Serotonergic overactivation of autonomic pathways produces the autonomic
    instability of the syndrome: tachycardia, diaphoresis, mydriasis, and
    diarrhea, with labile blood pressure in severe cases.
  downstream:
  - target: Tachycardia
    causal_link_type: DIRECT
  - target: Hyperhidrosis
    causal_link_type: DIRECT
  - target: Mydriasis
    causal_link_type: DIRECT
  - target: Diarrhea
    causal_link_type: DIRECT
  - target: Hypertension
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:24358002
    reference_title: "Serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "a combination of mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity"
    explanation: Names autonomic hyperactivity as one of the three clinical domains.
phenotypes:
- name: Agitation
  category: Behavioral
  description: Altered mental status with agitation, one domain of the clinical triad.
  phenotype_term:
    preferred_term: Agitation
    term:
      id: HP:0000713
      label: Agitation
  evidence:
  - reference: PMID:12925718
    reference_title: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia"
    explanation: Agitation is one of the Hunter criteria features, named explicitly.
- name: Clonus
  description: >-
    Inducible, spontaneous, or ocular clonus; the most discriminating sign in the
    Hunter criteria.
  phenotype_term:
    preferred_term: Clonus
    term:
      id: HP:0002169
      label: Clonus
  evidence:
  - reference: PMID:12925718
    reference_title: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia were needed for accurate prediction of serotonin toxicity"
    explanation: Clonus is the central discriminating feature of the Hunter decision rules.
  - reference: PMID:41853658
    reference_title: Chronic tramadol abuse as a cause of serotonin syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
    explanation: A chronic-tramadol case documenting inducible ankle clonus on examination.
- name: Hyperreflexia
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: PMID:12925718
    reference_title: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia"
    explanation: Hyperreflexia is one of the Hunter criteria features.
- name: Tremor
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:2035713
    reference_title: "The serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The most frequent clinical features are changes in mental status, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor."
    explanation: Tremor is among the most frequently reported features.
- name: Myoclonus
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:2035713
    reference_title: "The serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "changes in mental status, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor"
    explanation: Myoclonus is among the most frequently reported features.
- name: Hyperhidrosis
  description: Diaphoresis, an autonomic feature.
  phenotype_term:
    preferred_term: Diaphoresis
    term:
      id: HP:0000975
      label: Hyperhidrosis
  evidence:
  - reference: PMID:2035713
    reference_title: "The serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, and tremor"
    explanation: Diaphoresis is among the most frequently reported features.
- name: Hyperthermia
  description: >-
    Elevated body temperature, muscular rather than hypothalamic in origin; the
    hallmark of severe serotonin syndrome and present in a minority of cases.
  phenotype_term:
    preferred_term: Hyperthermia
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:33196298
    reference_title: "Fatal serotonin syndrome: a systematic review of 56 cases in the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "frequently observed features include hyperthermia, seizures, and high CK activities"
    explanation: Hyperthermia is a frequently observed feature of fatal serotonin syndrome.
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "only relatively few cases may present with hyperthermia"
    explanation: Grounds the statement that hyperthermia is present in only a minority of cases.
- name: Muscle rigidity
  description: >-
    Muscle rigidity and hypertonia, a severe-end neuromuscular feature and a
    Hunter criterion, present in roughly 45% of cases. When prominent, rigidity
    can mask the hyperreflexia and myoclonus used to diagnose the syndrome,
    making it harder to recognize.
  phenotype_term:
    preferred_term: Hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
  evidence:
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Of neurological symptoms, tremor and hyperreflexia were most frequently reported followed by muscle rigidity/hypertonia"
    explanation: Muscle rigidity/hypertonia is among the most frequently reported neurological signs.
  - reference: PMID:41111752
    reference_title: "Identifying Early Presentation of Serotonin Syndrome in a 20-Year-Old Man Prescribed Clomipramine and Quetiapine: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "muscle rigidity masked the hyperreflexia and myoclonus often used to diagnose serotonin syndrome, making it even more difficult to recognize"
    explanation: Rigidity can obscure the hyperreflexia and myoclonus the diagnosis relies on.
- name: Seizure
  description: >-
    Seizures occur mainly in severe serotonin syndrome - a review of fatal cases
    and a massive-overdose case - and are not common across all presentations.
    The serotonergic attribution is not universal: a rat study found that
    tramadol-overdose seizures, often read as a serotonin-syndrome feature, are
    mainly GABAergic rather than serotonergic.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33196298
    reference_title: "Fatal serotonin syndrome: a systematic review of 56 cases in the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "frequently observed features include hyperthermia, seizures, and high CK activities"
    explanation: Seizures are a frequently observed feature of fatal serotonin syndrome.
  - reference: PMID:41348645
    reference_title: "Time Course of Serum Dextromethorphan Concentrations in a Case of Serotonin Syndrome After Massive Overdose."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He developed serotonin syndrome with spontaneous clonus and seizures, requiring diazepam, sedation, intubation, and ventilation."
    explanation: A massive-overdose case with spontaneous clonus and seizures at the severe end.
  - reference: PMID:36297366
    reference_title: Investigation of the Mechanisms of Tramadol-Induced Seizures in Overdose in the Rat.
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    directness: INDIRECT
    snippet: "Management of tramadol-poisoned patients should take into account that tramadol-induced seizures are mainly related to a GABAergic pathway."
    explanation: >-
      Refutes the serotonergic attribution for tramadol-overdose seizures
      specifically: the rat data point to a GABAergic mechanism, so not every
      seizure in a serotonergic-drug patient is a serotonin-syndrome feature.
- name: Coma
  description: >-
    At the severe end of the mental-status spectrum, delirium can progress to coma.
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:41084074
    reference_title: "Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "more severe symptoms including fever, delirium, and coma"
    explanation: Coma is named among the severe manifestations of serotonin syndrome.
- name: Hypertension
  description: Hypertension, an autonomic feature.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Tachycardia, hypertension and fever were the most common autonomic symptoms."
    explanation: Hypertension is reported as one of the most common autonomic symptoms.
  - reference: PMID:41853658
    reference_title: Chronic tramadol abuse as a cause of serotonin syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
    explanation: A chronic-tramadol case with documented hypertension (140/100 mmHg).
- name: Tachycardia
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Tachycardia, hypertension and fever were the most common autonomic symptoms."
    explanation: Tachycardia is reported as one of the most common autonomic symptoms in the case meta-analysis.
- name: Mydriasis
  phenotype_term:
    preferred_term: Mydriasis
    term:
      id: HP:0011499
      label: Mydriasis
  evidence:
  - reference: PMID:30315014
    reference_title: "Demystifying serotonin syndrome (or serotonin toxicity)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "nervousness, insomnia, nausea, diarrhea, tremor, and dilated pupils"
    explanation: Dilated pupils (mydriasis) are listed among the features of serotonin toxicity.
  - reference: PMID:41853658
    reference_title: Chronic tramadol abuse as a cause of serotonin syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Physical examination revealed diaphoresis, mydriasis, tachycardia (130 beats/min), hypertension (140/100 mmHg), hyperreflexia, and inducible ankle clonus"
    explanation: A chronic-tramadol case documenting mydriasis on examination.
- name: Diarrhea
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:30315014
    reference_title: "Demystifying serotonin syndrome (or serotonin toxicity)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "nervousness, insomnia, nausea, diarrhea, tremor, and dilated pupils"
    explanation: Diarrhea is listed among the features of serotonin toxicity.
- name: Rhabdomyolysis
  description: Muscle breakdown with elevated creatine kinase, a complication of severe disease.
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  evidence:
  - reference: PMID:33196298
    reference_title: "Fatal serotonin syndrome: a systematic review of 56 cases in the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Creatine kinase (CK) activities were elevated (>3 times of the upper limit of normal) in eighteen patients, and it was very high (>25,000 IU/L) in four patients."
    explanation: Markedly elevated CK documents rhabdomyolysis in severe and fatal cases.
  - reference: PMID:41652380
    reference_title: "Sertraline and quetiapine induced Serotonin Syndrome and Neuroleptic Malignant Syndrome: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "creatine phosphokinase (CPK) concentration of 20,930 U/L"
    explanation: >-
      A severe overdose case with markedly elevated CPK documenting
      rhabdomyolysis; this patient met criteria for both serotonin syndrome and
      neuroleptic malignant syndrome, so it does not isolate serotonin syndrome
      as the cause.
treatments:
- name: Discontinuation and supportive care
  description: >-
    The primary treatment is stopping the offending serotonergic agent and
    providing supportive care - intravenous fluids, sedation, and external
    cooling. Most cases resolve within about 24 hours of withdrawal.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:2035713
    reference_title: "The serotonin syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Discontinuation of the suspected serotonergic agent and institution of supportive measures are the primary treatment"
    explanation: States drug withdrawal plus supportive care as the primary treatment.
- name: Cyproheptadine
  description: >-
    Cyproheptadine, a 5-HT2A receptor antagonist, is the specific antidote for
    moderate serotonin syndrome. In the rat model the most potent 5-HT2A
    antagonists tested (ritanserin, pipamperone) completely prevent the
    hyperthermia and death, which is the mechanistic rationale for
    antiserotonergic therapy; cyproheptadine itself was protective only at high
    doses in that model and is used infrequently in fatal human cases.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cyproheptadine
      term:
        id: CHEBI:4046
        label: cyproheptadine
  target_mechanisms:
  - target: Overactivation of Postsynaptic 5-HT Receptors
    treatment_effect: INHIBITS
    description: >-
      Cyproheptadine blocks 5-HT2A receptors, opposing the receptor
      overactivation that drives the syndrome.
    evidence:
    - reference: PMID:11164765
      reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: "potent 5-HT(2A) receptor antagonists are the most effective drugs for treatment of the 5-HT syndrome"
      explanation: >-
        5-HT2A antagonism is the mechanistic basis for antidotal therapy;
        cyproheptadine is the clinical 5-HT2A antagonist, demonstrated in the
        rat model.
  evidence:
  - reference: PMID:16227063
    reference_title: "Toxin-induced hyperthermic syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "administering either a central serotonergic antagonist, such as cyproheptadine or chlorpromazine, a benzodiazepine, or a combination of the two"
    explanation: Names cyproheptadine as the central serotonergic antagonist used in treatment.
- name: Benzodiazepine sedation
  description: >-
    Benzodiazepines control agitation and the neuromuscular hyperactivity, and
    in the animal model attenuate the development of hyperthermia.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: diazepam
      term:
        id: CHEBI:49575
        label: diazepam
  target_mechanisms:
  - target: Neuromuscular Hyperexcitability
    treatment_effect: INHIBITS
    description: >-
      GABA-enhancing sedation dampens the neuromuscular hyperactivity and
      slows the development of hyperthermia.
    evidence:
    - reference: PMID:12620284
      reference_title: "Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      directness: INDIRECT
      snippet: "Pre-treatment with diazepam, 10 and 20mg/kg, and chlormethiazole, 50 and 100mg/kg, attenuated the development of hyperthermia."
      explanation: >-
        GABA-enhancing drugs attenuate the hyperthermia in the rat model,
        supporting benzodiazepine use against the neuromuscular state; an
        animal-model inference.
  evidence:
  - reference: PMID:16227063
    reference_title: "Toxin-induced hyperthermic syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "a central serotonergic antagonist, such as cyproheptadine or chlorpromazine, a benzodiazepine, or a combination of the two"
    explanation: Names benzodiazepines among the standard treatments.
environmental:
- name: Electroconvulsive therapy concurrent with serotonergic agents
  description: >-
    Electroconvulsive therapy can precipitate serotonin syndrome when given to a
    patient already taking serotonergic drugs. ECT is thought to enhance central
    serotonergic neurotransmission, superimposing on the existing drug-raised
    serotonergic load. In a reported case the syndrome developed after the first
    ECT session in a patient on bupropion, trazodone, and quetiapine, and did not
    recur once the concurrent agents were changed.
  evidence:
  - reference: PMID:25970280
    reference_title: "Serotonin syndrome after electroconvulsive therapy in a patient on trazodone, bupropion, and quetiapine: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Serotonin syndrome developed soon after she received the first session of electroconvulsive therapy (ECT)."
    explanation: Documents ECT precipitating serotonin syndrome in a patient on serotonergic agents.
  influences_mechanisms:
  - target: Excess Synaptic Serotonin
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      ECT superimposed on serotonergic drugs precipitates the syndrome,
      consistent with ECT adding serotonergic drive on top of the drug-raised
      synaptic serotonin.
    evidence:
    - reference: PMID:25970280
      reference_title: "Serotonin syndrome after electroconvulsive therapy in a patient on trazodone, bupropion, and quetiapine: a case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The superimposing effect of ECT in conjunction with serotonergic agents might contribute to the development of serotonin syndrome."
      explanation: Attributes the episode to ECT acting on top of the serotonergic drug load.
  notes: >-
    No ECTO exposure class exists for electroconvulsive therapy (searched
    l~electroconvulsive, l~electroshock, l~electric in sqlite:obo:ecto, all
    empty), so exposure_term is omitted rather than bound to an approximate term.
- name: Cocaine overdose
  exposure_term:
    preferred_term: exposure to cocaine
    term:
      id: ECTO:9000265
      label: exposure to cocaine
  description: >-
    Cocaine inhibits presynaptic reuptake of serotonin (along with dopamine and
    norepinephrine), raising synaptic serotonin, so a massive cocaine overdose
    can precipitate serotonin syndrome - here as part of a fatal multi-system
    cocaine toxidrome that also included toxic leukoencephalopathy and central
    diabetes insipidus, which are separate cocaine effects rather than part of
    the serotonergic mechanism.
  evidence:
  - reference: PMID:42764931
    reference_title: "Cocaine-Induced Toxic Leukoencephalopathy, Serotonin Syndrome, and Central Diabetes Insipidus Following Cocaine Overdose: A Case Report of a Fatal Outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a fatal case of a 44-year-old man presenting with toxic leukoencephalopathy, serotonin syndrome, and central diabetes insipidus following a massive cocaine overdose"
    explanation: Documents serotonin syndrome following a massive cocaine overdose.
  influences_mechanisms:
  - target: Excess Synaptic Serotonin
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Cocaine's inhibition of presynaptic serotonin reuptake raises synaptic
      serotonin, the route by which a cocaine overdose drives the syndrome.
    evidence:
    - reference: PMID:42764931
      reference_title: "Cocaine-Induced Toxic Leukoencephalopathy, Serotonin Syndrome, and Central Diabetes Insipidus Following Cocaine Overdose: A Case Report of a Fatal Outcome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "Its primary pharmacological action involves the inhibition of presynaptic dopamine, norepinephrine, and serotonin reuptake, resulting in an excessive accumulation of synaptic catecholamines and monoamines"
      explanation: >-
        Cocaine blocks serotonin reuptake, the mechanism by which it raises
        synaptic serotonin and can precipitate the syndrome.
- name: Ayahuasca combined with a serotonergic agent
  description: >-
    Ayahuasca is an Amazonian botanical brew whose beta-carboline alkaloids
    (harmine, harmaline, tetrahydroharmine) are reversible MAO-A inhibitors. That
    MAOI activity predisposes users to serotonin syndrome when ayahuasca is
    combined with another serotonergic agent - here over-the-counter
    dextromethorphan - the same high-risk MAOI-plus-serotonergic-drug pairing
    that causes the syndrome with prescription MAOIs.
  evidence:
  - reference: PMID:42713547
    reference_title: "Severe Serotonin Syndrome With Acute Respiratory Failure Following Ayahuasca and Dextromethorphan Use: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present the case of a 46-year-old man who developed severe serotonin syndrome (SS) complicated by acute respiratory failure after ingesting ayahuasca over three days, followed by over-the-counter dextromethorphan (DXM) and diphenhydramine"
    explanation: Documents severe serotonin syndrome after ayahuasca combined with dextromethorphan.
  influences_mechanisms:
  - target: Excess Synaptic Serotonin
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Ayahuasca's beta-carboline MAO-A inhibition blocks serotonin breakdown, so
      combined with another serotonergic agent it raises synaptic serotonin and
      precipitates the syndrome.
    evidence:
    - reference: PMID:42713547
      reference_title: "Severe Serotonin Syndrome With Acute Respiratory Failure Following Ayahuasca and Dextromethorphan Use: A Case Report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "the MAOI content of ayahuasca predisposes users to serotonergic toxicity when combined with other serotonergic agents"
      explanation: >-
        The MAO-inhibiting content of ayahuasca is the route by which it raises
        serotonergic tone and precipitates the syndrome in combination.
  notes: >-
    No ECTO exposure class exists for ayahuasca or its alkaloids (searched
    l~ayahuasca, l~harmine, l~dimethyltryptamine in sqlite:obo:ecto, all empty),
    so exposure_term is omitted rather than bound to an approximate term.
- name: Kava supplement use with serotonergic agents
  description: >-
    Kava (Piper methysticum) is an over-the-counter botanical supplement. A
    pediatric case developed prolonged, cyproheptadine-refractory serotonin
    syndrome during daily kava use while transitioning between two SNRIs
    (duloxetine to venlafaxine). The authors propose that kavalactone CYP2D6 and
    monoamine oxidase inhibition raised the SNRI and active-metabolite levels. It
    is recorded as a reported association rather than a pathograph trigger: the
    proposed mechanism is offered as a possibility in a single case with a
    concurrent SNRI overlap, so kava's own role is unconfirmed and no
    `influences_mechanisms` link is asserted.
  evidence:
  - reference: PMID:40510098
    reference_title: "Prolonged Serotonergic Symptoms in a Pediatric Patient: Suspected Interaction Between Prescription Medications and Kava Supplement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present a pediatric patient who developed prolonged serotonin syndrome after daily use of kava while transitioning from duloxetine to venlafaxine."
    explanation: Documents serotonin syndrome associated with kava use during an overlapping-SNRI transition.
  - reference: PMID:40510098
    reference_title: "Prolonged Serotonergic Symptoms in a Pediatric Patient: Suspected Interaction Between Prescription Medications and Kava Supplement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several kavalactones have demonstrated significant CYP2D6 and monoamine oxidase inhibition, which in this case may have led to higher neuronal cleft serotonin-norepinephrine reuptake inhibitor drug and active metabolite concentrations"
    explanation: >-
      The proposed kava mechanism, recorded with its hedge: kavalactone CYP2D6/MAO
      inhibition may have raised SNRI and metabolite levels, offered as a
      possibility in this one case.
  notes: >-
    Mechanism proposed but unconfirmed: the authors suggest kavalactone CYP2D6
    and MAO inhibition raised the SNRI/metabolite levels ("may have led to"),
    reported in a single case alongside a concurrent duloxetine-to-venlafaxine
    transition, so kava's independent role is not established and no
    influences_mechanisms link is asserted. No ECTO exposure class exists for
    kava or Piper methysticum (searched l~kava, l~piper methysticum in
    sqlite:obo:ecto, both empty).
diagnosis:
- name: Hunter Serotonin Toxicity Criteria
  description: >-
    Diagnosis is clinical. The Hunter criteria apply decision rules over clonus,
    agitation, diaphoresis, tremor, hyperreflexia, hypertonicity, and
    temperature in a patient on a serotonergic agent. In their derivation study
    they were reported as more sensitive and specific than the older Sternbach
    criteria, and are widely treated as the reference standard; a later
    case meta-analysis (PMID:27406219) found that superiority rests on that one
    study and that the three criteria systems agree poorly, so the advantage is
    not independently established.
  evidence:
  - reference: PMID:12925718
    reference_title: "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These new criteria were simpler, more sensitive (84% vs. 75%) and more specific (97% vs. 96%) than Sternbach's criteria."
    explanation: Reports the diagnostic performance of the Hunter criteria in their derivation study.
  - reference: PMID:27406219
    reference_title: "Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "There is little agreement between current criteria systems for the diagnosis of serotonin syndrome."
    explanation: >-
      The case meta-analysis finds poor agreement between the criteria systems,
      qualifying the reported Hunter superiority.
differential_diagnoses:
- name: Neuroleptic malignant syndrome
  disease_term:
    preferred_term: neuroleptic malignant syndrome
    term:
      id: MONDO:0019790
      label: neuroleptic malignant syndrome
  description: >-
    The principal differential. Both present with hyperthermia, autonomic
    instability, altered mental status, and increased muscle tone, and the two
    overlap most in agents with both antidopaminergic and serotonergic activity.
    They separate on tempo and on the neuromuscular pattern: serotonin syndrome
    comes on within hours with clonus and hyperreflexia, whereas neuroleptic
    malignant syndrome evolves over days as an idiosyncratic reaction to
    neuroleptics with bradykinesia and lead-pipe rigidity.
  distinguishing_features:
  - Serotonin syndrome has clonus and hyperreflexia; neuroleptic malignant syndrome has bradykinesia and lead-pipe or cogwheel rigidity.
  - Serotonin syndrome follows a serotonergic agent and onsets within hours; neuroleptic malignant syndrome is an idiosyncratic reaction to neuroleptics evolving over days.
  evidence:
  - reference: PMID:30315014
    reference_title: Demystifying serotonin syndrome (or serotonin toxicity).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Unlike serotonin toxicity, neuroleptic malignant syndrome is not dose-related but is an idiosyncratic reaction to neuroleptic drugs. Onset is slower, taking place over days, and it is differentiated from serotonin toxicity by the presence of bradykinesia and lead-pipe or cogwheel rigidity"
    explanation: States the tempo and neuromuscular features that distinguish the two.
  - reference: PMID:16227063
    reference_title: Toxin-induced hyperthermic syndromes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "NMS typically occurs over hours to days in a patient taking a neuroleptic agent; its recommended treatment is generally the combination of a central dopamine agonist, bromocriptine or L-dopa, and dantrolene"
    explanation: Contrasts NMS tempo, trigger, and treatment with serotonin syndrome.
  - reference: PMID:41652380
    reference_title: "Sertraline and quetiapine induced Serotonin Syndrome and Neuroleptic Malignant Syndrome: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient met the diagnostic criteria for both Serotonin Syndrome and Neuroleptic Malignant Syndrome"
    explanation: >-
      The two can overlap: a sertraline-plus-quetiapine case met criteria for
      both, which is why the distinction can be difficult at the bedside.
  - reference: PMID:28943544
    reference_title: "Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The differential diagnosis of MS and SS is often difficult"
    explanation: A general-hospital series confirms the two are often hard to separate.
  - reference: PMID:28943544
    reference_title: "Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MS occurs more frequently than SS in the general hospital setting."
    explanation: In that series neuroleptic malignant syndrome was the more common of the two.
- name: Malignant hyperthermia of anesthesia
  disease_term:
    preferred_term: malignant hyperthermia of anesthesia
    term:
      id: MONDO:0018493
      label: malignant hyperthermia of anesthesia
  description: >-
    Shares severe hyperthermia and muscle rigidity, but is triggered by volatile
    anaesthetics during or shortly after surgery rather than by serotonergic
    drugs, and is treated with dantrolene. It is one of the drug/toxin-induced
    hyperthermic syndromes whose triggers and treatments differ from serotonin
    syndrome.
  distinguishing_features:
  - Triggered by specific volatile anaesthetics in the surgical/anaesthesia setting, not by serotonergic agents.
  - Treated with dantrolene; serotonin syndrome responds to withdrawal of the serotonergic agent plus supportive care and a 5-HT2A antagonist.
  evidence:
  - reference: PMID:30315014
    reference_title: Demystifying serotonin syndrome (or serotonin toxicity).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Malignant hyperthermia is triggered by specific volatile anesthetics during or shortly after surgery"
    explanation: States the anaesthetic trigger that distinguishes malignant hyperthermia from serotonin syndrome.
  - reference: PMID:16227063
    reference_title: Toxin-induced hyperthermic syndromes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "MH presents rapidly with jaw rigidity, hyperthermia, and hypercarbia. Although it almost always occurs in the setting of surgical anesthesia, cases have occurred in susceptible individuals during exertion. The treatment of MH involves the use of dantrolene"
    explanation: Gives the surgical-anaesthesia setting and dantrolene treatment that differentiate it from serotonin syndrome.
- name: Anticholinergic toxicity
  description: >-
    Overlaps through hyperthermia, agitation, mydriasis, and tachycardia, but
    is distinguished at the bedside by normal muscle tone and reflexes and by
    dry, flushed skin and absent bowel sounds, against the clonus,
    hyperreflexia, and diaphoresis of serotonin syndrome.
  distinguishing_features:
  - Muscle tone and reflexes are normal in anticholinergic toxicity, unlike the hyperreflexia and clonus of serotonin syndrome.
  - Anticholinergic toxicity gives dry, flushed skin and decreased bowel sounds; serotonin syndrome instead gives diaphoresis.
  evidence:
  - reference: PMID:30315014
    reference_title: Demystifying serotonin syndrome (or serotonin toxicity).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "A distinguishing feature is that muscle tone and reflexes are normal in anticholinergic toxicity"
    explanation: The normal tone and reflexes of anticholinergic toxicity separate it from serotonin syndrome.
  - reference: PMID:30315014
    reference_title: Demystifying serotonin syndrome (or serotonin toxicity).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Symptoms include dry mouth, dry and flushed skin, urinary retention, decreased bowel sounds, dilated pupils, blurry vision, fever, agitation, delirium, and hallucinations"
    explanation: Gives the dry, flushed skin and decreased bowel sounds of anticholinergic toxicity, against the diaphoresis of serotonin syndrome.
- name: Alcohol withdrawal syndrome
  disease_term:
    preferred_term: alcohol withdrawal
    term:
      id: MONDO:0005433
      label: alcohol withdrawal
  description: >-
    In a patient with alcohol use disorder who is also on serotonergic
    medication, serotonin syndrome can masquerade as alcohol withdrawal: both
    give tremor, diaphoresis, autonomic instability, and agitation. What resolves
    the case is the medication history, a symptom course that runs beyond the
    expected withdrawal window, and clonus and hyperreflexia that meet the Hunter
    criteria in a patient on serotonergic agents, pointing to serotonin syndrome.
  distinguishing_features:
  - Clonus and hyperreflexia that meet the Hunter criteria in a patient on serotonergic agents point to serotonin syndrome.
  - Serotonin syndrome tracks the serotonergic medication and can continue beyond the typical alcohol-withdrawal timeframe, rather than following the time since the last drink.
  evidence:
  - reference: PMID:40886730
    reference_title: "Serotonin Syndrome Masquerading as Alcohol Withdrawal: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alcohol withdrawal syndrome (AWS) and serotonin syndrome (SS) share several overlapping symptoms, complicating diagnosis in patients with alcohol use disorder (AUD) on serotonergic treatment"
    explanation: States the overlap that makes alcohol withdrawal a differential for serotonin syndrome.
  - reference: PMID:40886730
    reference_title: "Serotonin Syndrome Masquerading as Alcohol Withdrawal: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurological examination revealed hyperreflexia, clonus, and persistent hypertension, fulfilling the Hunter Serotonin Toxicity Criteria for SS"
    explanation: Clonus and hyperreflexia fulfilling the Hunter criteria resolve the case toward serotonin syndrome.
  - reference: PMID:40886730
    reference_title: "Serotonin Syndrome Masquerading as Alcohol Withdrawal: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he developed worsening tremors, nausea, diarrhea, diaphoresis, muscle twitching, rigidity, and restlessness beyond the typical AWS timeframe"
    explanation: The symptom course running beyond the expected withdrawal window is what prompted reconsideration toward serotonin syndrome.
discussions:
- discussion_id: ss_diagnostic_consensus
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What are the agreed terminology, diagnostic criteria, and boundaries of
    serotonin syndrome, now that it presents at therapeutic doses and across
    non-toxicology settings rather than only as overdose in psychiatric patients?
  attaches_to:
  - diagnosis#Hunter Serotonin Toxicity Criteria
  rationale: >-
    The entry already carries the measured disagreement between the Hunter,
    Sternbach and Radomski criteria (PMID:27406219). The broader problem is that
    the syndrome's terminology, clinical boundaries, etiology and pathophysiology
    remain unsettled decades after its description, and the classic
    toxicology/overdose picture does not match the milder, therapeutic-dose cases
    now reported from perioperative, neurology, cardiology and pediatric
    settings. Until a consensus definition exists, prevalence, criterion
    performance and even which presentations count as serotonin syndrome are all
    moving targets.
  evidence:
  - reference: PMID:38855279
    reference_title: "Serotonin syndrome controversies: A need for consensus."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Since SS is a potentially lethal illness, consensus is required on several concerns related to SS."
    explanation: A review arguing that terminology, criteria and pathophysiology of serotonin syndrome still lack consensus.
animal_models:
- name: Rat clorgyline plus 5-HTP serotonin syndrome model
  species: Rat
  genotype: Wild-type rats dosed with clorgyline (MAO-A inhibitor) and 5-hydroxy-L-tryptophan
  publication: PMID:11164765
  description: >-
    The standard pharmacological rat model: an MAO-A inhibitor plus a serotonin
    precursor drives rectal temperature above 40 degrees C with death within 90
    minutes, accompanied by a large anterior-hypothalamic noradrenaline surge.
    Potent 5-HT2A antagonists abolish both.
  modeled_mechanisms:
  - target: Central Noradrenergic Hyperactivity
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: >-
      Reproduces the hypothalamic noradrenaline surge and shows it is suppressed
      by 5-HT2A blockade.
    limitations: >-
      A precursor-plus-MAOI induction in a single species; it omits the human
      drug-combination context and species differences in 5-HT receptor
      distribution.
    readouts:
    - name: Anterior hypothalamic noradrenaline
      target: Central Noradrenergic Hyperactivity
      direction: INCREASED
      interpretation: Microdialysis measure of the noradrenergic surge in the model.
      evidence:
      - reference: PMID:11164765
        reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The noradrenaline (NA) levels in the anterior hypothalamus, measured by microdialysis, increased to 15.9 times the preadministration level."
        explanation: Quantifies the hypothalamic noradrenaline rise this readout measures.
  - target: Hyperthermia
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    description: Reproduces the lethal hyperthermia of severe serotonin syndrome.
    limitations: >-
      Supraphysiological precursor loading drives a more fulminant course than
      most human cases; the model captures the severe end of the spectrum.
    readouts:
    - name: Rectal temperature
      target: Hyperthermia
      direction: INCREASED
      interpretation: Core temperature rise, the model's primary endpoint.
      evidence:
      - reference: PMID:11164765
        reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "the rectal temperature of the rats increased to more than 40 degrees C, and all of the animals died by 90 min after the drug administration"
        explanation: Documents the hyperthermia and lethality this readout measures.
  evidence:
  - reference: PMID:11164765
    reference_title: "Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "both potent 5-HT(2A) receptor antagonists, completely prevented the increase in rectal temperature and death of the animals"
    explanation: >-
      5-HT2A antagonists abolish the model's hyperthermia, supporting it as an
      informative model of the receptor-driven mechanism.
📚

References & Deep Research

References

1
PMID:12925718
The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Serotonin Syndrome · 2026-10-02T02:00:57Z · View source

De-novo curation of serotonin syndrome (MONDO:0018546), a drug-induced toxidrome. Deep research requested from falcon via --fallback; no falcon key, so claude_code produced the report (frontmatter records fell_back). Report was honest about unverified claims; every snippet in the entry comes from independently fetched PubMed records. Causal chain: excess synaptic serotonin -> 5-HT2A/5-HT1A receptor overactivation -> neuromuscular hyperexcitability / central noradrenergic hyperactivity / autonomic hyperactivity -> clinical triad, with sustained muscle activity -> hyperthermia and rhabdomyolysis. Mechanism and treatment rationale anchored to the Nisijima rat clorgyline+5-HTP model (5-HT2A antagonists abolish hyperthermia and the hypothalamic NA surge; animal edges graded MODEL_ORGANISM/INDIRECT). Clinical features from Sternbach PMID:2035713, Volpi-Abadie PMID:24358002, Hunter criteria PMID:12925718, Werneke meta-analysis PMID:27406219, fatal-case review PMID:33196298. Treatments: discontinuation/supportive (NCIT:C15747), cyproheptadine (5-HT2A antagonist, CHEBI:4046) INHIBITS the receptor node, benzodiazepine sedation. No causal gene or inheritance (acquired toxidrome); pharmacogenetic modifiers noted as unestablished. Hyperthermia bound to HP:0001945 (Fever) not HP:0002047 (Malignant hyperthermia). Validated: validate-disorders 32/32 snippets, entity-refs, causal-targets, enum, duplicate-keys, coarse-phenotypes, model-scale-audit all clean; 12/12 phenotypes causally connected; GeneReviews NO_CHAPTER.

Claude Code ▸
Serotonin Syndrome (Serotonin Toxicity): Research Report
claude-haiku-4-5-20251001, claude-sonnet-5-5 1 citations 2026-10-02T01:49:23.325880

Serotonin Syndrome (Serotonin Toxicity): Research Report

Citation status. I checked these PMIDs against PubMed this session, and the titles match. Quoted abstract text is limited to the abstracts I retrieved. - PMID:2035713 Sternbach 1991, Am J Psychiatry - PMID:15784664 Boyer & Shannon 2005, N Engl J Med (no abstract text was returned) - PMID:24358002 Volpi-Abadie 2013, Ochsner J - PMID:27406219 Werneke 2016, BMC Neurol - PMID:33378846 Werneke 2020, J Integr Neurosci - PMID:10941349 Mason 2000, Medicine (Baltimore) - PMID:9034418 Mason 1997, Ann Pharmacother

Hunter criteria (Dunkley 2003) is PMID:12925718, from an author and title search. I did not retrieve its record.

My first-recall PMIDs for Boyer, Sternbach and Dunkley were all wrong. Anything below tagged [unverified] comes from general knowledge, has no PMID, and must be sourced before it goes into the knowledge base. Frequencies, odds ratios and incidence figures are mostly in that category. I did not retrieve primary data on them.

1. Disease Information

Overview. Serotonin syndrome (SS), also called serotonin toxicity, is an acute, potentially life-threatening drug-induced condition. Excess serotonergic activity at central and peripheral 5-HT receptors causes mental-status change, neuromuscular hyperactivity and autonomic hyperactivity.

"Serotonin syndrome is a potentially life-threatening syndrome that is precipitated by the use of serotonergic drugs and overactivation of both the peripheral and central postsynaptic 5HT-1A and, most notably, 5HT-2A receptors." (PMID:24358002, human clinical review)

The condition can follow therapeutic dosing, intentional overdose, or drug interactions (PMID:24358002).

Identifiers. The MONDO ID given in the template is MONDO:0018546. I did not verify it. Run just validate-terms or an OAK lookup before binding it. ICD-10-CM T43.2X- (poisoning by other antidepressants) with G90.5-style codes is [unverified], and so are the MeSH and ICD-11 identifiers. There is no OMIM or Orphanet entry, because this is an acquired toxic syndrome and not a Mendelian disease.

Synonyms. Serotonin toxicity and serotonin toxidrome. "Serotonin storm" is informal and [unverified].

Data source. The literature is case reports, case series, poison-center series and reviews. Disease-level criteria are derived from aggregated case data (Hunter criteria, PMID:12925718). Werneke (PMID:27406219) is a meta-analysis of individual cases.

Classification. Dismech should probably treat this as a drug-induced adverse-reaction entry, not a heritable disease. See the "side effect as mechanism" family in CLAUDE.md and the design-decisions register on scope.

2. Etiology

  • Causal factors. Exposure to one or more serotonergic agents. Sternbach's review states the most common cause is an interaction "between serotonergic agents and monoamine oxidase inhibitors" (PMID:2035713).
  • Drug classes implicated (classes are standard textbook content, [unverified] per drug):
  • SSRIs, SNRIs, TCAs and MAOIs (the highest-risk partner for combinations).
  • Opioids with serotonergic activity: tramadol, meperidine, fentanyl, methadone. Case support: tramadol with sertraline (PMID:9034418).
  • Linezolid, methylene blue, triptans, lithium, buspirone, trazodone.
  • Dextromethorphan (case: PMID:18007217, pediatric ingestion).
  • Bupropion (case: PMID:20238197).
  • St John's wort, tryptophan, and drugs of abuse such as MDMA, amphetamines and cocaine.
  • Risk factors.
  • Polypharmacy with two or more serotonergic mechanisms, including MAOI combinations.
  • Rapid dose escalation, overdose, and switching without adequate washout.
  • Genetic risk: CYP2D6 poor-metabolizer status and serotonin-transporter or receptor polymorphisms are hypothesized. This is [unverified], with no established causal variant.
  • Protective factors. None established. Prevention is mainly avoidance of risky combinations (see §13).
  • Gene–environment interaction. Pharmacogenetic influence on drug exposure (CYP2D6, CYP2C19) is plausible and [unverified].

3. Phenotypes

The syndrome is a triad (PMID:24358002). The HPO IDs below are suggestions that must be looked up before binding, and frequencies are not sourced. The Sternbach features are stated in PMID:2035713.

Phenotype Type Suggested HPO (verify) Notes
Altered mental status, agitation, confusion Behavioral/sign Confusion; Agitation Mental-status change is part of the triad (PMID:24358002)
Restlessness Symptom Restlessness PMID:2035713
Myoclonus Sign Myoclonus PMID:2035713
Hyperreflexia, clonus (inducible, ocular, spontaneous) Sign Hyperreflexia; Clonus Central to the Hunter criteria (PMID:12925718)
Tremor Sign Tremor PMID:2035713
Diaphoresis Sign Hyperhidrosis PMID:2035713
Shivering Sign Shivering PMID:2035713
Hyperthermia Sign Hyperthermia Present in only a minority of cases (PMID:27406219)
Mydriasis, tachycardia, diarrhea, hypertension Signs Mydriasis; Tachycardia; Diarrhea Autonomic, [unverified]
Rigidity (lower limbs greater than upper) Sign Muscle rigidity Severe cases, [unverified]
Rhabdomyolysis, elevated CK, metabolic acidosis Laboratory Rhabdomyolysis; Elevated serum creatine kinase Severe cases, [unverified]

Characteristics. - Onset. Typically rapid after the drug exposure, but Werneke found "not all cases seem to be of rapid onset" (PMID:27406219). - Severity. Ranges from mild to life-threatening. - Course. Resolution "typically resolves within 24 hours, but confusion can last for days, and death has been reported" (PMID:2035713). - Hyperthermia. "Only relatively few cases may present with hyperthermia" (PMID:27406219). - Quality of life. No data retrieved. It is a self-limited acute illness for most patients.

4. Genetic/Molecular Information

  • Causal genes. None. It is not a Mendelian disease.
  • Modifier and susceptibility candidates (all [unverified]): CYP2D6 and CYP2C19 (drug clearance), SLC6A4 (serotonin transporter), HTR2A (receptor), MAOA, and TPH2.
  • Epigenetics and chromosomal abnormalities. Not applicable.
  • When a gene is added to genetic:, use relationship_type: MODIFIER or SUSCEPTIBILITY. Do not use CAUSATIVE.

5. Environmental Information

  • Exposures. Pharmacological only, with the agents listed in §2. For ECTO binding, search the exact exposure terms and record the queries, per the dismech-terms rules. Use environmental[].influences_mechanisms with environmental_effect: TRIGGERS.
  • Lifestyle. Recreational drugs (MDMA, cocaine) and supplements (St John's wort, tryptophan) are [unverified] as to relative contribution.
  • Infectious agents. None.

6. Mechanism / Pathophysiology

Causal chain (steps 1–4 and 6 are textbook-level; sources are PMID:24358002, PMID:2035713 and PMID:33378846, and step 5 is inferred): 1. A serotonergic drug, or a combination, is taken. Mechanisms include increased synthesis (tryptophan), increased release (amphetamines, MDMA), reduced reuptake (SSRIs, SNRIs, TCAs), reduced metabolism (MAOIs, linezolid, methylene blue), or direct agonism (buspirone, triptans, LSD). 2. Extracellular serotonin (5-HT) rises or the receptors are directly stimulated. This leads to 3. over-activation of postsynaptic 5-HT receptors, "most notably 5HT-2A" and also 5-HT1A (PMID:24358002). This leads to 4. neuromuscular hyperactivity (clonus, hyperreflexia, tremor, rigidity), autonomic instability, and altered mental status. 5. In severe cases, sustained muscle activity produces hyperthermia, rhabdomyolysis and acidosis. This step is inferred, not shown as a demonstrated mechanism in the retrieved sources. 6. Multi-organ complications follow: DIC, renal failure and death.

Branching. The pharmacology differs by trigger. MAOI plus another serotonergic drug causes massive synaptic 5-HT, while overdose of a reuptake inhibitor causes a more graded rise. The 5-HT2A contribution to hyperthermia, and the role of 5-HT1A in the mild to moderate presentation, are debated and [unverified] here.

Suggested ontology terms (look up before binding; none are verified): - GO: serotonin receptor signaling pathway; serotonin uptake and metabolic process. - CL: serotonergic neuron; skeletal muscle fiber. - CHEBI: serotonin; the individual drugs.

Molecular profiling, single-cell and spatial data, multi-omics, CRISPR screens. I found none.

7. Anatomical Structures Affected

  • Primary. Central nervous system. The key serotonergic nuclei are the brainstem raphe nuclei [unverified], with projections to the cortex and spinal cord.
  • Peripheral. Skeletal muscle (hyperactivity), gut (diarrhea, since most body 5-HT is enterochromaffin-derived [unverified]), and the autonomic nervous system.
  • Secondary. Kidney (rhabdomyolysis-related injury) and the hematologic system (DIC) in severe cases.
  • Subcellular. Plasma membrane 5-HT receptors and presynaptic terminals.
  • Laterality. Bilateral and symmetric.

8. Temporal Development

  • Onset. Any age, acute to subacute. Rapid onset is typical, but not universal (PMID:27406219).
  • Stages. Mild, moderate and severe grades are used clinically (PMID:24358002 describes a spectrum), but I did not retrieve a staging source.
  • Course. Self-limited once the offending agent is stopped (PMID:2035713). A long half-life agent or a MAOI can prolong it.
  • Critical period. The first hours after a new combination or dose change. This is clinical lore and [unverified].

9. Inheritance and Population

  • Inheritance. Not applicable. Do not add an inheritance: block.
  • Epidemiology. I did not retrieve incidence data. Specific incidence figures, poison-center counts and the proportion of antidepressant-treated patients affected are [unverified]. Mild cases are likely underrecognized (PMID:24358002 emphasizes awareness and diagnostic accuracy).
  • Demographics. There is no known sex or ethnic predilection. Pediatric cases occur, for example after dextromethorphan (PMID:18007217) and in a 12-year-old with a mixed SS/NMS presentation (PMID:30964850).

10. Diagnostics

  • Diagnosis is clinical. There is no confirmatory laboratory test.
  • Criteria.
  • Sternbach (PMID:2035713), the original system.
  • Hunter Serotonin Toxicity Criteria (Dunkley, PMID:12925718).
  • Werneke's meta-analysis found "little agreement between current criteria systems for the diagnosis of serotonin syndrome" (PMID:27406219).
  • The Hunter criteria, with their emphasis on clonus and hyperreflexia, are widely preferred. That preference is [unverified] by the sources I retrieved.
  • Differential diagnosis. Neuroleptic malignant syndrome (NMS), anticholinergic toxicity, malignant hyperthermia, sepsis and CNS infection, and withdrawal states. NMS and SS can be hard to separate (PMID:30964850, PMID:32940904). Distinguishing features are onset tempo, clonus and hyperreflexia (SS) versus bradyreflexia and "lead-pipe" rigidity (NMS). The distinctions are [unverified] in the sources I read.
  • Laboratory work-up. CK, electrolytes, renal function, coagulation, ABG and drug screen, to look for complications and exclude mimics ([unverified]).
  • Genetic testing, imaging, screening. Not applicable.

11. Outcome / Prognosis

  • Most cases resolve within about 24 hours of stopping the agent (PMID:2035713).
  • "Death has been reported" (PMID:2035713). I did not retrieve mortality rates.
  • Complications in severe cases: rhabdomyolysis, DIC, renal failure and seizures ([unverified]).
  • Prognostic factors. Severity at presentation, extent of hyperthermia, and the offending agent's half-life ([unverified]).

12. Treatment

  • Core management (PMID:2035713): "discontinuation of the suspected serotonergic agent and institution of supportive measures."
  • Supportive care. IV fluids, sedation with benzodiazepines, and external cooling. NCIT: Supportive Care (NCIT:C15747, listed in CLAUDE.md).
  • Pharmacological antidote. Cyproheptadine, a 5-HT2A antagonist, is the usual choice for moderate cases. I have not retrieved a source for its efficacy and it needs one. Chlorpromazine and olanzapine are alternatives, and I have not sourced those either.
  • Severe disease. Intubation, paralysis with a non-depolarizing agent, and ICU care. Antipyretics are ineffective because the hyperthermia is muscular, not hypothalamic. All [unverified].
  • Case-level report. Propofol therapy after dextromethorphan ingestion (PMID:18007217); management of severe hypertension in SS (PMID:30886699).
  • Pharmacogenomics. No guideline-level recommendation found.
  • Clinical trials. I did not search ClinicalTrials.gov. No randomized trials of treatment are known to me, and that is [unverified].
  • Suggested NCIT terms (look up each CURIE, don't copy): Supportive Care NCIT:C15747; Pharmacotherapy NCIT:C15986 with therapeutic_agent bound to CHEBI for cyproheptadine.

13. Prevention

  • Primary. Avoid combining serotonergic agents. Observe MAOI washout intervals (about 2 weeks for most, longer for fluoxetine [unverified]). Use prescribing alerts. Educate clinicians and patients (PMID:24358002).
  • Secondary and tertiary. Early recognition and drug withdrawal prevent progression. After an episode, document the culprit combination and avoid re-challenge.
  • Vaccines, screening, genetic counseling. Not applicable.

14. Other Species / Natural Disease

  • Serotonin toxicity occurs in dogs and cats (e.g., after SSRI or 5-HTP ingestion), and I did not retrieve a citation. It is [unverified].
  • NCBITaxon IDs to bind after lookup: Canis lupus familiaris, Felis catus.
  • OMIA does not apply, since this is not a heritable disease.
  • Not zoonotic.

15. Model Organisms

  • Rodent models are drug-induced (MAOI plus a serotonin precursor or releaser, or direct agonists such as 5-MeO-DMT). The behavioral "serotonin syndrome" scoring in rats and mice (forepaw treading, hindlimb abduction, Straub tail, tremor) is textbook content and [unverified] here.
  • Fidelity. Reproduces the neuromuscular and thermoregulatory signs. The limits are species differences in 5-HT receptor distribution and the absence of the human drug-combination context.
  • In dismech, put animal data under animal_models: and link it to the pathograph with modeled_mechanisms. Use evidence_source: MODEL_ORGANISM.
  • Genetic models (e.g., SERT or MAOA knockouts, Tph2 manipulations) are [unverified].

Curation notes for dismech

  • Entry type. Likely a DISEASE (drug toxidrome) with no genes or inheritance. Check the stub's entry_type first.
  • Mechanism chain nodes to model:
  • Serotonergic drug exposure.
  • Increased synaptic serotonin.
  • 5-HT2A (and 5-HT1A) over-activation.
  • Neuromuscular hyperactivity.
  • Hyperthermia and rhabdomyolysis.
  • Evidence still needed. Each of these is [unverified] above and needs a sourced PMID with an exact abstract quote (via just fetch-reference): Hunter criteria, cyproheptadine efficacy, incidence, mortality, and the CYP2D6 and other genetic contributions.
  • Hunter criteria. just fetch-reference PMID:12925718 before citing.
  • Boyer & Shannon (PMID:15784664). No abstract text was returned. Fetch it into references_cache/ and quote from there.

Sources (retrieved this session)

  • PubMed E-utilities esearch, esummary and efetch for the PMIDs listed at the top, e.g. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&id=15784664,24358002,2035713,27406219,33378846

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 7
Quoted claims found in source 7
Quoted claims not found in source 0
References weighed for topical relevance 13
On topic 6
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 3
Resolved 3
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0

Every term resolved, and every label the report gave matched.